about
Drug-induced renal damage in preterm neonates: state of the art and methods for early detectionPattern of NSAID use in the Italian general population: a questionnaire-based surveyLiver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemTorsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropePro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across EuropeAssessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy.QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unitThe hERG K+ channel: target and antitarget strategies in drug development.hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey.Gastric motor effects of triptans: open questions and future perspectives.Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.New developments in the treatment of functional dyspepsia.Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.Review of the implications of dietary tryptophan intake in patients with irritable bowel syndrome and psychiatric disorders.Pharmacology of serotonin: what a clinician should know.Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.Inflammatory neuropathies of the enteric nervous system.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.Antibacterial macrolides: a drug class with a complex pharmacological profile.Diagnosis and therapy of irritable bowel syndrome.Adherence to chronic cardiovascular therapies: persistence over the years and dose coverageEnteric neuroplasticity evoked by inflammation.Drug development for the irritable bowel syndrome: current challenges and future perspectivesExposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodStrategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia.The beta3-adrenoceptor as a therapeutic target: current perspectives.Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.Role of drugs and devices in patients at risk of sudden cardiac death.Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling.Excipients in medicinal products used in gastroenterology as a possible cause of side effects.Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden.Animal models of chemically induced intestinal inflammation: predictivity and ethical issues.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
P50
Q26849339-7CB3F20C-3C48-4B96-85A0-0348FB440686Q28171365-20E65137-E464-4977-841D-2A48D9BE211AQ28257188-004D56D2-2B60-432D-866E-97777170FBE3Q28535299-8842387B-0D0B-4691-96F6-E97832E5FFF3Q28544621-2CD605BC-9C36-4C55-B5E4-B1364CCB3D11Q30852962-29006FDF-8A79-4AE0-A134-D523B70B443CQ30978981-2E18A3B8-0196-49AF-9D1B-698BDB5A8594Q33151796-249C4FE2-0E45-429B-8505-68974AB860CAQ33428656-1CE633E9-2DF8-4F66-A215-C98BB8F26DF9Q33542747-E4F49B3D-1589-4C0F-B0E7-B038A708F85EQ33568454-E184F15C-29AC-4222-8E31-670B288B72FFQ33845529-EDC74E5A-5D43-4109-A63D-830E2BE85D4AQ33845924-AD520291-DC65-403D-B722-6B59F1C5AFEDQ33984538-A9FE9A5F-A74E-4317-AF30-B9412A73821AQ34278893-EAD8867D-3677-4906-95DF-382E84B0F004Q34336897-AEADCC00-5D1C-4D0E-BEA4-253475329969Q34808260-CCBB06D5-842F-44D6-95B8-C8FF0745A37AQ35100294-02949788-8D96-4F04-A6E5-6A57A27AB47CQ35270090-E665D654-0AD2-4AAA-8E1F-D6DB5D59E584Q35563537-0A5DECC0-2165-4B01-9F88-D2F7CACE8338Q35596862-9CB642B1-5173-4EAA-B771-C4DD3F6A5B85Q35669824-2523DAFE-97C2-4118-A090-ED3025F5F974Q35799504-08491EEE-981E-4422-8052-5A5DD201D715Q35819331-3E6532C3-739C-4C6B-B194-BA869FC33326Q35822239-2D7E47AD-E12A-4B25-A58A-19BC05A57786Q35873847-A0FA48F4-C88C-4DBB-B34C-CCEC4CA2E10BQ36025030-0653D9F5-21DF-4DE4-A419-08245EF84D0AQ36453671-3E47380A-2016-4C8D-8B13-0357B7A7A2ABQ36579818-CD0AC0C9-7CE2-4DF6-A7D5-2C1AB7FDD51CQ37156289-E5F3CA89-8BBC-4B9A-8805-B7DEA1F6080BQ37294291-0E4D893E-61E3-465B-A8AB-32EB0AC8DC40Q37476217-E163F202-E621-4CF1-8093-E36B8B729110Q37624003-AAB11573-1472-4610-95AD-2A79A5C683D3Q37770595-739A7A7D-0FAE-4BEB-98E4-BC832D64E145Q37815218-7F45AE03-14C4-4FBB-8D9C-BC97E006DB85Q37847467-4CAAC961-CBD8-4AA4-A4B5-5DD5D3AC5639Q37967508-5832010C-B054-4181-BE56-0713135AD57EQ38039947-311D8677-506A-413A-99A4-C8BEC76CA678Q38096805-F780FA7C-E964-4E60-A51B-AF6A0286DAC9Q38175457-B22EA339-0798-4E5D-A191-DAA41C57F152
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabrizio De Ponti
@ast
Fabrizio De Ponti
@en
Fabrizio De Ponti
@es
Fabrizio De Ponti
@nl
Fabrizio De Ponti
@sl
type
label
Fabrizio De Ponti
@ast
Fabrizio De Ponti
@en
Fabrizio De Ponti
@es
Fabrizio De Ponti
@nl
Fabrizio De Ponti
@sl
prefLabel
Fabrizio De Ponti
@ast
Fabrizio De Ponti
@en
Fabrizio De Ponti
@es
Fabrizio De Ponti
@nl
Fabrizio De Ponti
@sl
P108
P106
P1153
55992097200
P21
P31
P496
0000-0002-0367-9595